Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierIn July 2017, we entered into a License Agreement (as amended, the “2017 LCA”) with Bioprojet Société Civile de Recherche (“Bioprojet”) whereby we acquired the exclusive right to commercialize the pharmaceutical compound pitolisant. Our lead product, WAKIX® (pitolisant) (“WAKIX”), is a first-in-class therapy with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $215M in Q1 2026 (quarter ended March 31, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $32M (15% of revenue). For the full year FY2025, revenue was $868M (+22% year on year) and net income $159M.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.